Hydralazine 50mg Extended-Release Tablets from Japan
Extended-release tablets providing 50mg hydralazine for once-daily dosing in managing chronic hypertension. Falls under HTS 3004.90.92.20 as a mixed product in measured doses for therapeutic cardiovascular use, put up for retail sale.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Verify extended-release mechanism compliance with FDA dissolution testing standards
• Provide detailed formulation specs including excipients to avoid reclassification as bulk chemical